Gastrointestinal involvement is common among patients with EGPA, with eosinophilic tissue infiltration, weight loss, and myalgia identified as significant predictors.

2,3 Depemokimab is currently being evaluated in phase III trials for the treatment of other IL-5 mediated diseases, including OCEAN for eosinophilic granulomatosis with polyangiitis (EGPA ... the ...

Iran sends conciliatory signals to leaders in Davos Iranian official Zarif tells critics 'let's talk' UN nuclear watchdog says Iran pushing hard on enrichment IAEA chief Grossi says dialogue ...

If your symptoms are serious or your doctor thinks something else is causing them, they might recommend a prescription medicine. Most people don't need any kind of treatment for mild cold symptoms.

Promising, but when they get to 20-30 hours nuclear engines will be much more plausible. (Also a good idea to make plans ahead of time for reprocessing/disposal of nuclear rocket engines and fuel ...

A STUDY has developed a predictive model for gastrointestinal (GI) lesions in patients with eosinophilic granulomatosis with polyangiitis (EGPA), shedding light on this serious complication and its ...

after reports that U.S. President Donald Trump had called Pyongyang "a nuclear power." Sign up here. Asia Pacificcategory Burmese refugee dies after discharge from shut US-funded clinic ...

The primary end point was histologic remission (defined as peak eosinophilic count ≤6 eos/hpf ... Future research should focus on these unmet needs, thus moving toward a precision medicine and a more ...

Languages: English, French As Iran and Russia deepened diplomatic ties on Friday, Russian President Vladimir Putin touted the possibility of new nuclear power units in Iran, according to Russian ...

It’s a pivotal moment for nuclear weapons. Tensions between the United States and Russia, the two major nuclear powers, are high. Longstanding nuclear pacts have crumbled. China, which trails ...

As the first interleukin (IL)-5-targeting monoclonal antibody in late-stage trials, Fasenra targets eosinophilic inflammation, potentially reshaping treatment standards and reinforcing AstraZeneca’s ...